Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma clinical trials

Explore recruiting smoldering multiple myeloma with high risk of progression to symptomatic myeloma clinical trials.

Also recruiting in Europe

Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma trials by city

Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Toronto Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Vancouver Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Montreal Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Calgary Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Edmonton Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Ottawa Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Winnipeg Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Quebec City Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Hamilton Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Kitchener Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in London Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Halifax Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in New York Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Los Angeles Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Chicago Smoldering Multiple Myeloma With High Risk Of Progression To Symptomatic Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease